Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05368818
Other study ID # CAIN457AGB06
Secondary ID
Status Completed
Phase
First received
Last updated
Start date December 7, 2020
Est. completion date May 6, 2021

Study information

Verified date June 2022
Source Novartis
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This was a retrospective, observational study of psoriasis patients treated with secukinumab, using secondary data from BADBIR. BADBIR is a UK/ROI pharmacovigilance registry that was initiated in 2007 to monitor the long-term safety of biologic drugs used to treat psoriasis. The study used longitudinal data within the registry to track the trends relating to the disease. For the analysis of improvement and patient reported QoL, patients with a minimum of one follow-up visit were included. The index date was defined as the date of initiation of secukinumab treatment, and follow-up visits were at 6-, 12-, 18-, & 24-months post-index.


Description:

The BADBIR data was current up until the 31st August 2019 for this analysis. Study period: From 1st July 2015, as secukinumab was included in BADBIR in January 2016 and patients backdated 6 months, to 31st August 2019. Identification period: From 1st July 2015 to 31st August 2019 was used to identify applicable patients for analysis. Index date: Initiation of secukinumab treatment within the BADBIR database.


Recruitment information / eligibility

Status Completed
Enrollment 767
Est. completion date May 6, 2021
Est. primary completion date May 6, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years to 99 Years
Eligibility Inclusion Criteria: Inclusion criteria for the biologic cohort: - Age =18 years at initiation of secukinumab. - At least one follow-up visit post-registry enrollment. - On-label dosing of secukinumab of 300mg. Inclusion criteria for the PsA biologic cohort: - Age =18 years at initiation of secukinumab. - At least one follow-up visit post-registry enrollment. - On-label dosing of secukinumab of 300mg. - Diagnosis of PsA at baseline. Exclusion Criteria: - The patient did not meet the criteria stated above.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Secukinumab
Included patients treated with Cosentyx (Secukinumab) in a retrospective analysis of the BADBIR data source

Locations

Country Name City State
United States Novartis Investigative Site East Hanover New Jersey

Sponsors (1)

Lead Sponsor Collaborator
Novartis Pharmaceuticals

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Proportion of patients reporting high/very high QoL changes from Baseline (BL) (from 2 or 3 at BL to 0) Patient reported QoL for five specific DLQI domains from baseline up to 24 months of UK/ROI psoriasis patients enrolled in BADBIR who were initiated on secukinumab treatment were reported.
Following 5 domains were included:
Embarrassment and/or self conciousness
Social leisure
Work/study
Problems relating to partner, friends and relatives
Sexual difficulties
throughout the study, approximately 4 years (1st July 2015 to 31st August 2019 )
Secondary Age Age was reported Baseline
Secondary Sex Sex information was reported Baseline
Secondary Ethinicity Ethinicity information was reported Baseline
Secondary Employment status Employment status was reported Baseline
Secondary Smoking Characteristics Smoking characteristics were reported Baseline
Secondary Weight Weight information was reported Baseline
Secondary Height Height information was reported Baseline
Secondary Body Mass Index (BMI) BMI information was reported Baseline
Secondary Waist circumference Waist information was reported Baseline
Secondary Absolute Psoriasis Area Severity Index (aPASI) at BL aPASI scores were reported Baseline
Secondary Total Dermatology Life Quality Index (DLQI) at BL Total DLQI score was reported Baseline
Secondary DQLI Domain - 2) embarrassment and/or self-consciousness - proportion of those who reported high or very high at baseline DQLI Domain - 2) embarrassment and/or self-consciousness - proportion of those who reported high or very high at baseline were reported Baseline
Secondary DQLI Domain - 5) social and leisure activities - proportion of those who reported high or very high at baseline DQLI Domain - 5) social and leisure activities - proportion of those who reported high or very high at baseline were reported Baseline
Secondary DQLI Domain - 7) work/study - proportion of those who reported high or very high at baseline DQLI Domain - 7) work/study - proportion of those who reported high or very high at baseline were reported Baseline
Secondary DQLI Domain - 8) problems relating to partner, friends, and relatives - proportion of those who reported high or very high at baseline DQLI Domain - 8) problems relating to partner, friends, and relatives - proportion of those who reported high or very high at baseline were reported Baseline
Secondary DQLI Domain - 9) sexual difficulties - proportion of those who reported high or very high at baseline DQLI Domain - 9) sexual difficulties - proportion of those who reported high or very high at baseline were reported Baseline
Secondary Number of Biologic naïve/experienced patients Patients were listed as being previously experienced to a biologic treatment if a drug name listed in 'Biologics_Drugname', was listed as a 'DrugName' in the DrugPastTherapy table. If a patient had no record of a biologic drugname in the DrugPastTherapy table, the patient was recorded as biologic naive. Baseline
Secondary Number of Psoriatic Arthritis (PsA) patients Patients were classified as Psoriatic Arthritis using the 'PsoriaticArthritis' flag in the Baseline_Psoriasis tables. (0=No, 1=Yes, Null=not entered). Baseline
Secondary Time to PsA diagnosis Time to PsA onset was calculated using the 'PsoriaticArthritisOnset' variable from the FupPsoriasis table and 'YearOnset' from the Baseline Psoriasis table. The time to PsA diagnosis was reported as the difference between 'PsoriaticArthritisOnset' minus 'YearOnset'. Baseline
Secondary Number of patients with No PsA and nail involvement Patients were classified as having nail involvement using the 'NailsNumber' variable from the Baseline_Psoriasis table Baseline
Secondary Number of nails involved Number of nails involved were reported Baseline
Secondary Number of patients with at least one Comorbidity Comorbidities were derived from the MedDRA Preferred Term (PT) variable in the BaselineComorbidities table. If a patient recorded at least one comorbidity, listed within the available data, this patient was recorded as "Has a comorbidity". Baseline
Secondary Number of patients with five most common comorbidities at BL Comorbidities were derived from the MedDRA Preferred Term (PT) variable in the BaselineComorbidities table. If a patient recorded at least one comorbidity, listed within the available data, this patient was recorded as "Has a comorbidity". The top 5 comorbidities at baseline were determined via highest frequency of occurrence by cohort and were reported for each subgroup Baseline
Secondary Frequency of on-label 300mg prescription Frequency of on-label 300mg prescription was categorized into the following, N/A (new convention for licensed dose), Once a week (induction), Once monthly & Once every four weeks. To determine if the patients were on-label, confirmation was required that the right dosage was being given; patients were included as on-label if they reported a dose value of 300 using the 'Dose' and the unit mg with the 'DoseUnit' variable in the DrugBiologicTherapy table. The frequency of prescription was assessed using the 'Frequency' variable and mapped in accordance with the following categories: N/A (new convention for licensed dose), Once a week (induction), Once monthly, once every four weeks or Not reported. Baseline
Secondary Proportion of PsA subjects with a total DLQI score of >10 Proportion of PsA subjects with a total DLQI score of >10 at baseline achieving a score of 0 or 1 at 6-month intervals to 24 months (window of +/- 60 days), stratified by none, any, <5 nails, =5 nails or all nails involved at baseline was reported. throughout the study, approximately 4 years (1st July 2015 to 31st August 2019)
Secondary Proportion of PsA patients with an aPASI score of 0, <=1, <=2 or <=3 Proportion of PsA patients with an aPASI score of 0, <=1, <=2 or <=3 at each 6-month interval up to 24 months (window of +/-60 days), stratified by none, any, <5 nails, =5 nails or all nails involved at baseline was reported. throughout the study, approximately 4 years (1st July 2015 to 31st August 2019)
Secondary Proportion of Psoriasis patients with an aPASI score of 0, <=1, <=2 or <=3 Proportion of Psoriasis patients with an aPASI score of 0, <=1, <=2 or <=3 at each 6-month interval up to 24 months (window of +/-60 days), stratified by patients being biologic naive or biologic experienced was reported. throughout the study, approximately 4 years (1st July 2015 to 31st August 2019)
See also
  Status Clinical Trial Phase
Completed NCT01194219 - Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis Phase 3
Recruiting NCT06030076 - A Study to Assess the Effects of Switching From a Biologic Treatment to Tildrakizumab Using Patient-reported Outcomes in Adult Participants With Moderate to Severe Plaque Psoriasis
Completed NCT04263610 - Efficacy and Safety of Tildrakizumab in Participants With Moderate-to-Severe Chronic Plaque Psoriasis Who Are Non-Responders to Dimethyl Fumarate Therapy Phase 4
Completed NCT02601469 - Study to Assess the Potential for Adrenal Suppression Following Treatment With DSXS in Patients With Plaque Psoriasis Phase 2
Completed NCT05600036 - A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Plaque Psoriasis Phase 2
Completed NCT05375955 - A Study to Learn About The Study Medicine (PF-07038124) In Patients With Mild To Moderate Atopic Dermatitis Or Mild To Severe Plaque Psoriasis. Phase 2
Completed NCT03614078 - A Study of PRCL-02 in Moderate to Severe Chronic Plaque Psoriasis Phase 2
Not yet recruiting NCT05036889 - A 16-week Randomized Evaluation of the Impact of Mind.Px Application on Response to Biologic Treatment in Patients Suffering From Plaque Psoriasis Through Clinical Utility and Health Outcomes. N/A
Completed NCT04603027 - A Phase 2 Study Investigating the Effect of EDP1815 in the Treatment of Mild to Moderate Plaque Psoriasis Phase 2
Completed NCT03638258 - The Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream in Subjects With Chronic Plaque Psoriasis Phase 2
Completed NCT02881346 - Efficacy and Tolerability of Enstilar® in Daily Practice
Recruiting NCT02611349 - Study to Evaluate the Long-Term Safety of IDP-118 Lotion in the Treatment of Plaque Psoriasis Phase 3
Completed NCT02251678 - Evaluate the Effect of Elimune Capsules Phase 1
Completed NCT01987843 - Dose-finding Study of MT-1303 in Subjects With Moderate to Severe Chronic Plaque Psoriasis Phase 2
Terminated NCT01708629 - Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects Phase 3
Completed NCT01230138 - Pivotal Efficacy and Safety Registration Trial of FP187 in Moderate to Severe Plaque Psoriasis Phase 2
Withdrawn NCT00747032 - To Demonstrate the Superior Efficacy of NYC 0462 Ointment Over That of the Placebo in the Treatment of Plaque Psoriasis Phase 3
Completed NCT00581100 - Effects of Etanercept on Nail Psoriasis and Plaque Psoriasis Phase 4
Suspended NCT01228656 - Effectiveness of Association Mometasone Furoate 0.1% and Salicylic Acid 5% Compared With Mometasone Furoate Phase 2
Completed NCT00540618 - A Phase II Study of MEDI-507, Administered by Injection to Adults With Psoriasis Phase 2